Anti-F126B/ FAM126B/ HYCC2 monoclonal antibody

Anti-F126B/ FAM126B/ HYCC2 antibody for FACS & in-vivo assay

Target products collectionGo to FAM126B/FAM126B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2117-Ab-1/ GM-Tg-hg-MP2117-Ab-2Anti-Human FAM126B monoclonal antibodyHuman
GM-Tg-rg-MP2117-Ab-1/ GM-Tg-rg-MP2117-Ab-2Anti-Rat FAM126B monoclonal antibodyRat
GM-Tg-mg-MP2117-Ab-1/ GM-Tg-mg-MP2117-Ab-2Anti-Mouse FAM126B monoclonal antibodyMouse
GM-Tg-cynog-MP2117-Ab-1/ GM-Tg-cynog-MP2117-Ab-2Anti-Cynomolgus/ Rhesus macaque FAM126B monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2117-Ab-1/ GM-Tg-felg-MP2117-Ab-2Anti-Feline FAM126B monoclonal antibodyFeline
GM-Tg-cang-MP2117-Ab-1/ GM-Tg-cang-MP2117-Ab-2Anti-Canine FAM126B monoclonal antibodyCanine
GM-Tg-bovg-MP2117-Ab-1/ GM-Tg-bovg-MP2117-Ab-2Anti-Bovine FAM126B monoclonal antibodyBovine
GM-Tg-equg-MP2117-Ab-1/ GM-Tg-equg-MP2117-Ab-2Anti-Equine FAM126B monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2117-Ab-1/ GM-Tg-hg-MP2117-Ab-2; GM-Tg-rg-MP2117-Ab-1/ GM-Tg-rg-MP2117-Ab-2;
GM-Tg-mg-MP2117-Ab-1/ GM-Tg-mg-MP2117-Ab-2; GM-Tg-cynog-MP2117-Ab-1/ GM-Tg-cynog-MP2117-Ab-2;
GM-Tg-felg-MP2117-Ab-1/ GM-Tg-felg-MP2117-Ab-2; GM-Tg-cang-MP2117-Ab-1/ GM-Tg-cang-MP2117-Ab-2;
GM-Tg-bovg-MP2117-Ab-1/ GM-Tg-bovg-MP2117-Ab-2; GM-Tg-equg-MP2117-Ab-1/ GM-Tg-equg-MP2117-Ab-2
Products NameAnti-FAM126B monoclonal antibody
Formatmab
Target NameFAM126B
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-FAM126B benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species F126B/ FAM126B/ HYCC2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2117
    Target NameFAM126B
    Gene ID285172,213056,316415,700818,488469,101093128,533324,100067910
    Gene Symbol and SynonymsC130065N10Rik,D1Ertd53e,D630010C10,FAM126B,HYCC2,RGD1309752
    Uniprot AccessionQ8IXS8
    Uniprot Entry NameF126B_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000155744
    Target ClassificationN/A

    The target: FAM126B, gene name: FAM126B, also named as HYCC2. Predicted to be involved in phosphatidylinositol phosphate biosynthetic process and protein localization to plasma membrane. Predicted to be located in cytosol. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.